Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs with hematologic disorders, cancer and rare immune diseases.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Rigel Pharmaceuticals news
04.05.2022
The loss of Rigel Pharmaceuticals under GAAP for the 3 months of 2022 was $27.445 million, against a profit of $39.5 million in the previous year. Revenue decreased 4.8 times to $16.735 million from $81.018 million the year before.
Source: 
rigel.com
rigel.com
02.03.2022
Rigel Pharmaceuticals' GAAP loss for 2021 was $17.914 million, down 39.8% from $29.744 million in the previous year. Revenue increased 37.4% to $149.236 million from $108.621 million a year earlier.
Source: rigel.com
rigel.com
03.11.2021
Rigel Pharmaceuticals reported a GAAP net profit of $4.727 million for 9M 2021, compared to a loss of $10.507 million in the previous year. Revenue increased 42.9% to $128.827 million from $90.171 million a year earlier.
Source: rigel.com
rigel.com
04.08.2021
Rigel Pharmaceuticals' GAAP net income for the six months of 2021 was $25.679 million, up 7 times from $3.667 million in the previous year. Revenue increased 49.5% to $107.284 million from $71.782 million a year earlier.
Source: rigel.com
rigel.com
General information
| Company name | Rigel Pharmaceuticals |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080 |
| Mailing address | 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080 |
| Website | www.rigel.com |
| Information disclosure | www.sec.gov |
English (US) 